-+ 0.00%
-+ 0.00%
-+ 0.00%

Sionna Therapeutics Initiates PreciSION CF Phase 2a POC Trial Evaluating SION-719, NBD1 Stabilizer, When Added To Trikafta, Current Standard Of Care In CF; Topline Data Expected In Mid-2026

Benzinga·10/21/2025 11:12:09
Listen to the news

SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis

Topline data expected in mid-2026

WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced initiation of the PreciSION CF Phase 2a proof-of-concept (POC) trial evaluating SION-719, a first-in-class nucleotide binding domain 1 (NBD1) stabilizer, when added to Trikafta® (elexacaftor/tezacaftor/ivacaftor), the current standard of care (SOC) in CF.